US OptionsDetailed Quotes
ADMA241018C20000
- 0.05
- -0.14-73.68%
15min DelayClose Oct 11 16:00 ET
0.20High0.05Low
0.11Open0.19Pre Close56 Volume898 Open Interest20.00Strike Price500.00Turnover88.70%IV16.94%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0898Delta0.0861Gamma228.60Leverage Ratio-0.0261Theta0.0002Rho20.54Eff Leverage0.0034Vega
ADMA Biologics Stock Discussion
Sign in to post a comment
$ADMA Biologics (ADMA.US)$ what's the story here 👀
1
$ADMA Biologics (ADMA.US)$ sweet I've been waiting for a dip
3
$ADMA Biologics (ADMA.US)$
Looking for 15 before jumping back in
Looking for 15 before jumping back in
Such a cool problem. Sorta.
We are growing much more confident in identifying growing companies.
The problem now is, when to take profit? When to re-open position?
For example, we rode $ADMA Biologics (ADMA.US)$ from before earnings to $18 and closed out. Except they will easily be more successful in the future - and have continued running. The balance when it is overbought to the momentum of the trend is tough!!
Another example is $Nanoviricides (NNVC.US)$ : we rode them to their 52-week high ...
We are growing much more confident in identifying growing companies.
The problem now is, when to take profit? When to re-open position?
For example, we rode $ADMA Biologics (ADMA.US)$ from before earnings to $18 and closed out. Except they will easily be more successful in the future - and have continued running. The balance when it is overbought to the momentum of the trend is tough!!
Another example is $Nanoviricides (NNVC.US)$ : we rode them to their 52-week high ...
5
ADMA Biologics Reports Strong Second Quarter 2024 Financial Results and Strategic Business Updates.
ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company specializing in manufacturing and marketing specialty biologics, has announced its financial results for the second quarter of 2024. The company reported growth in revenue, net income, and adjusted EBITDA, reflecting the robustness of its operations a...
ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company specializing in manufacturing and marketing specialty biologics, has announced its financial results for the second quarter of 2024. The company reported growth in revenue, net income, and adjusted EBITDA, reflecting the robustness of its operations a...
2
No comment yet
74483586 : ［Hamlet］![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")